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A B S T R A C T
Butyrylcholinesterase (BuChE) is considered a promising drug target as it plays an important role in the pro-
gression of late stage Alzheimer’s disease (AD). Two compound libraries were selected and 64 124 amine
containing moieties were screened using a hierarchical virtual screening protocol to discover new selective
BuChE inhibitors. From these and subsequent docking experiments, 9-phenylacridinedione (9-PAD) was iden-
tified as a promising scaffold for selective inhibition of BuChE. Selected top dock scored 9-PADs were assayed
and compounds 3 and 6 exhibited potent and highly selective human BuChE inhibition (IC50: 98 nM and 142 nM,
respectively). Both molecules were also predicted to show sufficient brain permeability, not have any substantial
toxicities, especially hepatotoxicity, and no significant in vitro cytotoxicity against SH-SY5Y neuroblastoma cells
at concentrations up to 100 µM. These findings indicate that 9-PAD is a promising lead structure for the de-
velopment of agents able to treat late stage AD.
Alzheimer’s disease (AD) is a devastating neurodegenerative dis-
order characterized by a progressive and steady deterioration in mental
capacity, combined with negative behavioural and psychiatric symp-
toms.1,2 Throughout the world it is estimated that 50 million people are
affected by dementia, with most cases linked to AD. This number is
predicted to increase 3-fold within the following 30 years.3 Therefore,
new and improved therapeutic agents are of the utmost importance in
order to curb this devastating disorder. The pathophysiology of AD is
complex and multifactorial, and researchers have proposed a variety of
mechanisms which contribute to the disease state.4 These include
cholinergic dysfunction,5,6 deposition of amyloid-β plaques,7 accumu-
lation of tau-proteins6,7 and oxidative stress.8
Current treatment options are mainly focussed on the cholinergic
hypotheses which states that degradation of acetylcholine (ACh) con-
taining neurons and subsequent shortage of the neurotransmitter ACh
contributes substantially to the cognitive decline associated with
AD.5,6,9 Hydrolysis of ACh in the CNS is mainly regulated by two
cholinesterase enzymes namely; acetylcholinesterase (AChE) and bu-
tyrylcholinesterase (BuChE).10 AChE is accountable for 80% of the ACh
activity and is almost 10 000 times more active at hydrolysing ACh than
BuChE under normal conditions.11,12 In addition, AChE is mainly found
in neurons and BuChE is generally expressed in glial- and endothelial
cells in the brain.13,14 Therefore, the use of AChE inhibitors such as
galanthamine,15 rivastigmine16 and donepezil17,18 have been the main
therapeutic approach used to increase ACh levels in neurons of patients
suffering from AD. However, studies have found that during the pro-
gression of AD the levels of AChE show a steady decrease, which in turn
leads to BuChE taking over the hydrolysis of ACh. Under these condi-
tions BuChE may increase by up to 165% of its usual physiological
level.19,20 Thus, BuChE and the subsequent inhibition thereof is a sug-
gested therapeutic target that may be beneficial for the treatment of
advanced stage AD. Furthermore, the development of highly selective
BuChE inhibitors may avoid some of the common cholinergic side ef-
fects associated with AChE inhibition.21 In recent years several selective
BuChE have been developed, including diarylinidazole-,22 cym-
serine-,23 benzofuran-24 and isosorbide-based25 compounds. However,
none of these compounds have made it further than in vitro studies, and
the need for the discovery of new selective BuChE inhibitors that may
make it to a drug candidate stage therefore still remains.
In order to develop highly selective inhibitors of the human BuChE
(huBuChE) enzyme, it is essential to study the differences in the protein
structures between human AChE (huAChE) and huBuChE, especially
within the active sites of the enzymes. The homology of huAChE and
huBuChE indicates that the two enzymes share 65% identical amino
acid arrangements with a similar general structure.26–28 The active sites
of the two enzymes are comprised of a catalytic anionic site and choline
binding pocket which are situated at the bottom of a ~20 Å deep gorge.
The main difference between these two enzymes are the presence and
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extent of sub-regions within the gorge which includes an acyl-binding
pocket and a peripheral anionic site (Fig. 1). The differences observed
in the acyl-binding site are especially important. In huAChE this site
accommodates two aromatic amino acids Phe295 and Phe297 which
are respectively replaced by aliphatic amino acids Leu286 and Val288
in huBuChE.26–28 Due to the presence of the two bulky phenylalanine
residues in the acyl binding pocket, binding and hydrolysis of larger
compounds are restricted in huAChE because of the smaller ligand
binding cavity volume.29 In huBuChE, replacement of these residues
with the two flexible smaller aliphatic amino acids allows this site to
accommodate larger compounds. This structural difference between the
active sites of these enzymes may therefore be strategically used in
order to identify highly selective inhibitors of the huBuChE enzyme.
In the present study, a structure-based virtual docking methodology
was applied in an attempt to identify novel highly selective huBuChE
inhibitors (Fig. 2, see Supplementary File S1 for experimental details).
To reach this objective, we screened a combination of the Maybridge
screening collection (https://www.maybridge.com) and AldrichCPR
(https://www.sigmaaldrich.com) compound databases. These data-
bases were selected because they contain structurally diverse purcha-
sable compounds, especially the Maybridge collection.31 In addition,
most of the compounds in these databases obey Lipinski’s “rule of
five”32 and also demonstrate good predicted ADME profiles, which
make them ideal candidates to identify drug-like compounds using
structure-based virtual screening experiments. Around 265 000 drug-
like compounds were compiled using these databases. As described in
the literature, the majority of known cholinesterase ligands contain
basic or permanently charged nitrogens. This is because acidic protein
residues lining both the CAS (Glu197 in huBuChE) and PAS (Asp70 in
huBuChE) are able to attract positively charged ligands.33,34 In addi-
tion, studies have indicated that amine containing compounds are able
to interact with the CAS through cation-π interactions.35,36 Therefore,
the compiled database was narrowed down using OGREP, a command-
line tool of OpenBabel 2.2.3,37 to a focused database of 64 124 com-
pounds bearing an amine moiety.
The initial virtual screen was performed using FRED 2.2.5 docking
software (OpenEye Scientific Software, Inc., Santa Fe, NM, USA;
www.eyesopen.com) and the huBuChE protein structure in complex
with tacrine (PDB: 4BDS).30 The amine moiety containing database was
docked into the active site cavity of huBuChE. The top pose of each
docked compound where at least one heavy atom was within close
proximity to Trp82 and one with Ser198 was then ranked according to
their respective Chemgausse3 scores.38–40 These custom constraints
were selected based on the known binding modes of inhibitors (e.g.
tacrine – PDB ID: 4BDS; decamethonium – PDB ID: 6EP4; ethopropazine
– PDB ID: 6EQP; propidium – PDB ID: 6ESJ and huperzine A – PDB ID:
1VOT) and substrates (e.g. choline, butyrate and glycerol – PDB IDs:
1P01 and 1P0M) within the active site of the enzyme.26–29 Results from
this initial screen indicated that 8 out of the top 40 scored compounds
consisted out of a 9-phenylacridinedione (9-PAD) scaffold or closely
related derivative thereof (see Supplementary File S2). To the best of
our knowledge 9-PADs have not yet been described in the literature as
ChE inhibitors. In addition, a number of structurally- and/or shape si-
milar compounds compared to the 9-PADs, such as dihydropyridine-
and phenothiazine derivatives, were also observed within the top 40
docked compounds. Both dihydropyridine- and phenothiazine deriva-
tives have been described in the literature as having ChE inhibitory
abilities.41-44 This prompted our interest to explore 9-PAD as a potential
novel scaffold able to inhibit huBuChE. In addition, 9-PAD has some
structural features similar to the known non-selective ChE inhibitor,
tacrine,45 which further justified additional investigation (Fig. 3).
In the next step, the ZINC drug-like compound database containing
around 11.3 million purchasable compounds was downloaded.46
OGREP was used to extract all compounds from the ZINC database
containing the 9-PAD scaffold.37 A total of 1374 9-PADs were identi-
fied. These 9-PADs were also docked using FRED 2.2.5 with huBuChE
(PDB: 4BDS)30 in the same manner as described for the initial screen.
The compounds were again ranked according to their Chemgauss3
score and the top 40 scored 9-PADs were selected for further in-
vestigation (see Supplementary File S3). In order to predict the se-
lectivity of the top 40 9-PADs for huBuChE over huAChE a further
docking experiment was done where the huAChE enzyme in complex
with donepezil (PDB: 4EY7)27 was used. FRED 2.2.5 docking software
predicted that none of the top 40 9-PADs would have the ability to
optimally bind to the huAChE active site, as none of the predicted
conformations were within the proximity of the custom constrained
amino acids Trp86 and Ser203.26–29 This may be due to the structural
bulkiness and/or orientation of the 9-PADs leading to their inability to
effectively pass through the narrow gorge and/or fit within the smaller,
compared to BuChE, active site of huAChE.
To confirm the promising results obtained from the docking ex-
periments, seven compounds (2–8) ranging within the top 40 scored 9-
Fig. 1. Surface maps of the active sites of huBuChE (PDB ID: 4BDS)30 and huAChE (PDB ID: 4EY7).27 The amino acids making up the acyl binding pocket (cyan),
choline binding pocket (red), peripheral anionic site (PAS, orange) and catalytic anionic site (CAS, magenta) of each respective enzyme are shown. The black arrows
indicate the entry direction of ligands and substrates.
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PADs were selected for further evaluation as initial proof-of-concept
(Table 1). Compound 1, an unsubstituted 9-PAD derivative, was not
scored within the top 500 9-PAD’s but was included as a reference to
explore the docking accuracy and ability to predict agents with potent
huBuChE inhibitory activities. The selection of these compounds was
also based on availability, ability to be shipped to South Africa and cost.
The binding interactions, conformation and orientation of the pur-
chased 9-PADs (1–8) within the huBuChE active site were investigated
(Table 1, Figs. 3–5). Interactions between the individual 9-PADs and
Trp82,26,47 Trp231,48 Ser198 and His43849,50 were considered sig-
nificant as these are important for inhibitory activity. Additionally, the
ability of these 9-PADs to access the acyl site is also substantially im-
portant for potential selectivity towards huBuChE as this pocket is
larger than in huAChE (Fig. 1).29
All the docked 9-PADs showed promising binding modes with the
acridinedione moiety binding in the same vicinity as the co-complexed
ligand, tacrine,30 and the methylbenzene moiety occupying the acyl-
binding pocket (Fig. 3). The phenyl moiety directly connected to the
acridinedione is orientated towards Asp70. In addition, the halogen or
methoxy substitutions on this phenyl group presides around the back-
bone atoms of Asp70 in the PAS, thus providing stability to the 9-PADs
at the entrance of the active site gorge. This observation is important as
the majority of the 9-PADs scored within the top-40 compounds (see
Supplementary File S2) contained substitutions at this position which
likely contributes to enhanced binding stability.
As for the binding interactions, compounds 1–3, 5 and 6 were able
to from a H-π interaction between Trp82 and the acridinedione moiety,
while the methylbenzene group forms a π − π interaction with Trp231.
The unsubstituted amine of the acridinedione was able to interact with
His438 through a hydrogen bond interaction (Table 1, Figs. 4 and 5).
The two compounds within this series containing a methyl substitution
on the amine moiety (4 and 7), lacked this interaction with His438.
This contributed to a slight shift in their binding orientation leading to a
loss of interactions with Trp82 and Trp231. Compound 8, containing
the sulfonate moiety also exhibited a lack of predicted binding inter-
actions with these tryptophan residues, but maintained an interaction
with His438. However, compounds 4, 7 and 8 still showed convenient-
binding modes within the huBuChE active site and should still exhibit
moderate huBuChE inhibitory activity based on these docking results
(Table 1, Figs. 4 and 5). It was noted that compounds 1–8 did not di-
rectly interact with the catalytic residue Ser198, which has been re-
ported as an important amino acid, amongst others, for cholinesterase
inhibition.26–29 However, the cyclohexanone group on the one side of
the acridinedione moiety in these 9-PADs points toward Ser198
(average distance between closest non-hydrogen atoms is 3.5 Å). This
therefore offers an opportunity for substitutions on this position of the
cyclohexanone group to potentially improve the potency of these
compounds.
In an attempt to further investigate the results from the initial
huAChE screen, the docking experiment was repeated for compounds
1–8. However, in this case the custom constraints were removed in
order for the binding modes to be generated. The results from the top
scored poses, indicated that the acridinedione moiety is orientated
Fig. 2. Flow scheme showcasing the hierarchical structure-based virtual screening protocol.
Fig. 3. Binding orientation of all selected 9-PADs (1–8, shown in gray) docked
into the active site cavity of huBuChE. Tacrine is shown in orange.
J. Joubert and E. Kapp Bioorganic & Medicinal Chemistry Letters 30 (2020) 127075
3
towards the PAS region within the proximity of the PAS amino acid
Asp74 (Fig. 6). This observation indicates that the acridine moiety
within these 9-PADs does not have the ability to effectively pass
through the narrow gorge separating the PAS and the CAS. Further-
more, tacrine is known to bind in close proximity to Trp86 and form a
π-π interaction with this residue in AChE.51 In the case of these 9-PADs
none were predicted to bind in this manner (Fig. 6). In addition, the 9-
PADs were unable to interact with the acyl binding pocket as was ob-
served in huBuChE, because of their structural bulkiness and less than
optimal orientation. Therefore, these 9-PADs are not expected to show
any significant huAChE inhibitory activity based on these docking re-
sults.
The eight compounds selected from the virtual screening results
were initially evaluated in vitro for their inhibition on equine BuChE
Table 1
ZINC ID, supplier, structures, dock scores and huBuChE active site binding interactions of 9-PADs 1–8 and tacrine.
Compound ZINC ID Supplier R1 R2 R3 R4 Chemgausse3 Score Interactions
1 627289 Sigma Aldrich –H –H –CH2– –H −12.24 Trp82, His438, Trp231
2 00689050 Molport –H –OCH2CH3 –CH2– –H −17.68 Trp82, His438, Trp231
3 00796178 Molport –H –OCH3 –CH2– p-fluoro −17.36 Trp82, His438, Trp231
4 01158419 Molport –CH3 –OCH3 –CH2– p-fluoro −17.04 Glu197
5 20109989 Molport –H –Br –CH2– –H −17.43 Trp82, His438, Trp231
6 1012743 Molport –H –Br –CH2– m-fluoro −17.82 Trp82, His438; Gly116, Trp231
7 01156953 Molport –CH3 –Cl –CH2– p-chloro −17.24 Glu197
8 20109979 Molport –H –O–CH3 –SO2– p-CH3 −17.20 Glu197, His438, Gly117
Tacrine 19014866 Sigma Aldrich – – – – n.d. Trp82
Fig. 4. Interaction maps of compounds 2, 3 and 4 within the huBuChE active site.
Fig. 5. Interaction maps of compounds 5, 6 and 8 within the huBuChE active site.
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(eqBuChE) and electric eel AChE (eeAChE), using a modified method of
Ellman,52 as previously described by our group.53–55 Inhibitory activ-
ities were observed for all the compounds with IC50 values ranging
between 0.242 and 6.01 µM (Table 2). What was interesting was that
compound 1 showed significantly less potent inhibition (between 3 and
28-fold) compared to the other evaluated 9-PADs. This is in line with
the docking experiments as 1 was not predicted within the top 500 9-
PADs. Therefore, this indicates that substitutions on the two phenyl
groups of these 9-PADs leads to a marked increase in activity. In ad-
dition, compounds 4 and 7 containing the -N-CH3 group was sig-
nificantly less potent than their secondary amine structural counter-
parts (1–3, 5, 6). This may be ascribed to the lack of important binding
interactions (i.e. with Trp82, His438 and Trp231, Fig. 4) as described in
the docking results (Table 1). The test compounds were further assayed
against eeAChE and the results indicated a high degree of selectivity for
eqBuChE for all compounds (Table 2, SI: 17 to 412). These inhibition
results revealed that 3 and 6 are the most potent and selective eqBuChE
inhibitors, with IC50 values of 0.243 µM and 0.388 µM, respectively.
Because of the promising inhibition and selectivity of 3 and 6 for
eqBuChE, our next step was to evaluate their inhibitory potential on
huBuChE and huAChE in vitro. Compared to eqBuChE, both 3 and 6
were around 2.5-times more active at inhibiting huBuChE, and showed
very limited huAChE inhibition (Table 3). Therefore, both 3 and 6 can
be considered as highly selective sub-micromolar inhibitors of hu-
BuChE. Furthermore, the inherent toxicity of 3 and 6 toward SH-SY5Y
cells was investigated utilizing a modified MTT assay described by our
group.54–56 The viability of the cells was not compromised by the test
compounds up to concentrations of 100 μM (Table 3). The MTT is a cell
proliferation assay, and these results indicates that there were low le-
vels of inhibition of cell proliferation, which would suggest the com-
pounds to be largely devoid of cytotoxicity. In addition, the compounds
were screened for potential toxicities on a number of toxicity targets
and blood-brain barrier (BBB) permeation using in silico models (see
Supplementary File S1, Table S1). Both compounds were predicted to
show limited toxicities and adequate ability to cross the BBB (Table 3).
It is also promising that none of the 9-PADs were predicted to show
hepatotoxicity, as is the case for tacrine that lead to its subsequent
removal from the pharmaceutical market (Supplementary File S1).
In conclusion, a structure-based virtual docking methodology was
employed in an attempt to discover novel highly selective huBuChE
inhibitors. From these and subsequent docking experiments, 9-pheny-
lacridinedione (9-PAD) was identified as a promising scaffold for se-
lective inhibition of the huBuChE enzyme. 9-PADs 3 and 6 demon-
strated the strongest inhibitory activities and were further tested
against huBuChE and huAChE. Both 3 and 6 showed a 2.5-fold increase
in huBuChE activity (IC50: 98 nM and 142 nM, respectively) compared
to eqBuChE. Only limited huAChE inhibition was observed, with 3
showing a 1275-fold selectivity for huBuChE. Both molecules were also
not predicted have any significant toxicities, especially hepatotoxicity,
or in vitro cytotoxicity against SH-SY5Y cells at concentrations up to
100 µM. The significant and highly selective BuChE inhibitory po-
tencies of these 9-PADs indicate that they could be used as promising
lead compounds for the development of new agents for the treatment of
late stage AD. It should also be noted that there are 1374 purchasable 9-
PADs available on the ZINC compound database46 and a larger biolo-
gical screening endeavour may identify available 9-PADs with even
greater therapeutic potential.
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Fig. 6. Binding orientation of representative 9-PADs 4 (purple) and 6 (yellow)
docked in the active site cavity of huAChE.
Table 2
In vitro IC50 values (µM ± SEM, n = 3) of test compounds for eqBuChE and
eeAChE.
Compound eqBuChE eeAChE (%)a SI BuChEb
1 6.010 ± 0.42 > 100 (24) > 17
2 0.752 ± 0.04 > 100 (19) > 133
3 0.242 ± 0.03 > 100 (27) > 412
4 2.440 ± 0.21 > 100 (33) > 41
5 0.633 ± 0.05 > 100 (14) > 158
6 0.388 ± 0.08 > 100 (22) > 258
7 1.658 ± 0.12 > 100 (23) > 60
8 0.959 ± 0.09 > 100 (15) > 104
Tacrine 0.110 ± 0.01 0.140 ± 0.03 > 1.27
aPercentage inhibition at 100 µM is indicated in brackets. beqBuChE selectivity
index = IC50 (eeAChE)/IC50 (eqBuChE). The selectivity was calculated at
100 µM on eeAChE because of solubility problems at higher concentrations.
Table 3
In vitro IC50 values (µM ± SEM, n = 3) of compounds 3 and 6 for huBuChE and huAChE. The in vitro cytoxicity (n = 3), in silico predicted toxicities and BBB
penetration are also included.
Compound huBuChE huAChE SI huBuChEb % Cytotoxicity at 100 µM Predicted toxicitiesd BBB penetratione
3 0.098 ± 0.02 125 ± 4.52 1275 14 ± 1.22 none Yes (94%)
6 0.142 ± 0.05 > 100 (39)a > 704c 18 ± 2.03 none Yes (97%)
Tacrine 0.044 ± 0.01 0.100 ± 0.05 2.27 n.d. Hepatotoxicity Yes (99%)
Mutagenicity
aPercentage inhibition at 100 µM indicated in brackets. beqBuChE selectivity index = IC50 (eeAChE)/IC50 (eqBuChE); cThe selectivity of compound 6 was calculated
at 100 µM on huAChE because of solubility problems at higher concentrations. dIn silico toxicity predictions were done using the Protox-II webserver (http://tox.
charite.de/protox_II). eCalculated using the admetSAR webserver (http://lmmd.ecust.edu.cn/admetsar2). Values presented in brackets indicate the % probability.
n.d. = not determined.
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